文章：

多发性骨髓瘤及其他浆细胞疾病患者全身低剂量CT获取、解读和报告的建议：IMWG骨工作组报告

Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group

原文发布日期：2018-10-04

DOI: 10.1038/s41408-018-0124-1

类型: Article

开放获取: 是

英文摘要：

Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myeloma Working Group (IMWG) criteria for multiple myeloma (MM) definition. Nevertheless, standardization guidelines for the optimal use of WBLDCT in MM patients are still lacking, preventing its more widespread use, both in daily practice and clinical trials. The aim of this report by the Bone Group of the IMWG is to provide practical recommendations for the acquisition, interpretation and reporting of WBLDCT in patients with multiple myeloma and other plasma cell disorders.

摘要翻译： 

全身低剂量CT（WBLDCT）作为浆细胞疾病患者骨病评估的一线影像学检查手段具有重要优势，并已被纳入2014年国际骨髓瘤工作组（IMWG）制定的多发性骨髓瘤（MM）诊断标准。然而，目前仍缺乏针对多发性骨髓瘤患者使用WBLDCT的标准化指南，这阻碍了该技术在临床日常实践和试验中的广泛应用。国际骨髓瘤工作组骨病小组的本报告旨在为多发性骨髓瘤及其他浆细胞疾病患者的全身低剂量CT影像采集、解读与报告提供实践性建议。

原文链接：

Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group